Allergic Rhinitis AND Asthma — The United Airway

The answer first

Allergic rhinitis and asthma are the upper and lower manifestations of a single "united airway" driven predominantly by allergen-specific type 2 (Th2) inflammation. ^[3] Roughly 20 to 60 percent of patients with allergic rhinitis have asthma, and the great majority of asthmatics have rhinitis; treating the nose with intranasal corticosteroid improves lower-airway outcomes, and uncontrolled rhinitis is a known trigger of exacerbations. ^[1]

A physician-level answer rests on four pillars: ^[1]

1. Confirm the diagnosis with a careful history (sneezing, rhinorrhoea, nasal itch, congestion, plus wheeze, chest tightness, dyspnoea) and demonstrate variable airflow limitation (FEV1/FVC improvement after bronchodilator ≥ 12 percent and 200 mL, or positive bronchoprovocation). Skin-prick testing or serum-specific IgE confirms atopy but does not diagnose either disease on its own.
2. Classify severity and control using ARIA for rhinitis (intermittent vs persistent, mild vs moderate-severe) and GINA for asthma (Steps 1 to 5), and screen for type 2 "high-T2" biomarkers (blood eosinophils ≥ 150/µL, FeNO ≥ 20 ppb, allergen-driven).
3. Treat the unified airway with intranasal corticosteroid for rhinitis and GINA stepwise inhaled corticosteroid (ICS)-containing therapy for asthma. Since 2019 GINA no longer recommends short-acting beta-2 agonist (SABA) monotherapy — all adults and adolescents receive ICS-formoterol as-needed (SMART) or daily ICS plus as-needed SABA. ^[2]
4. Escalate to biologics when standard therapy fails: omalizumab for severe allergic asthma, mepolizumab or benralizumab for severe eosinophilic asthma, dupilumab or tezepelumab for broader T2-high asthma. ^[5]

DWE high-yield: "SABA-only is OUT." From 2019 GINA no longer recommends reliever-only short-acting beta-2 agonist treatment for adults and adolescents, because reliever use without inhaled corticosteroid increases exacerbation and mortality risk. All patients should now have ICS delivered either daily or via the as-needed ICS-formoterol reliever (AIR/SMART regimen). ^{[2] [4]}

References12ShowHide

1. [1]Brożek JL, Bousquet J, Agache I, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol, 2017.PMID 28602936
2. [2]Levy ML, Bacharier LB, Bateman E, et al. Key recommendations for primary care from the 2022 Global Initiative for Asthma (GINA) update. NPJ Prim Care Respir Med, 2023.PMID 36754956
3. [3]Bellanti JA, Settipane RA United airway disease. Allergy Asthma Proc, 2014.PMID 25295801
4. [4]Reddel HK, Bateman ED, Schatz M, et al. A Practical Guide to Implementing SMART in Asthma Management. J Allergy Clin Immunol Pract, 2022.PMID 34666208
5. [5]Hanania NA, Alpan O, Hamilos DL, et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med, 2011.PMID 21536936
6. [6]Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med, 2014.PMID 25199059
7. [7]FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (SIROCCO): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial. Lancet, 2016.PMID 27609406
8. [8]Clarridge K, Chin S, Eworuke E, et al. A Boxed Warning for Montelukast: The FDA Perspective. J Allergy Clin Immunol Pract, 2021.PMID 33744471
9. [9]Seidman MD, Gurgel RK, Lin SY, et al. Clinical practice guideline: Allergic rhinitis. Otolaryngol Head Neck Surg, 2015.PMID 25644617
10. [10]Creticos PS, Gunaydin FE, Nolte H, et al. Allergen Immunotherapy: The Evidence Supporting the Efficacy and Safety of Subcutaneous Immunotherapy and Sublingual Immunotherapy. J Allergy Clin Immunol Pract, 2024.PMID 38685477
11. [11]Seccia V, Baldini C, Latorre M, et al. Focus on the Involvement of the Nose and Paranasal Sinuses in Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss Syndrome): Nasal Cytology Reveals Infiltration of Eosinophils as a Very Common Feature. Int Arch Allergy Immunol, 2018.PMID 29393242
12. [12]Bousquet J, Schünemann HJ, Togias A, et al. Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. J Allergy Clin Immunol, 2020.PMID 31627910